Gao Xinlong, Zuo Xu, Min Tianjiao, Wan Yu, He Ying, Jiang Beier
Naval Medical Center of PLA, Shanghai, China.
College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Front Pharmacol. 2024 Jun 4;15:1388903. doi: 10.3389/fphar.2024.1388903. eCollection 2024.
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy with historically high mortality rates. The treatment strategies for AML is still internationally based on anthracyclines and cytarabine, which remained unchanged for decades. With the rapid advance on sequencing technology, molecular targets of leukemogenesis and disease progression related to epigenetics are constantly being discovered, which are important for the prognosis and treatment of AML. Traditional Chinese medicine (TCM) is characterized by novel pharmacological mechanisms, low toxicity and limited side effects. Several biologically active ingredients of TCM are effective against AML. This review focuses on bioactive compounds in TCM targeting epigenetic mechanisms to address the complexities and heterogeneity of AML.
急性髓系白血病(AML)是一种异质性血液系统恶性肿瘤,历来死亡率很高。AML的治疗策略在国际上仍以蒽环类药物和阿糖胞苷为基础,几十年来一直未变。随着测序技术的迅速发展,与表观遗传学相关的白血病发生和疾病进展的分子靶点不断被发现,这对AML的预后和治疗很重要。中药具有新颖的药理机制、低毒性和有限的副作用。中药的几种生物活性成分对AML有效。这篇综述聚焦于针对表观遗传机制的中药生物活性化合物,以应对AML的复杂性和异质性。